Praxis Precision Medicine...
66.00
1.98 (3.09%)
At close: Jan 14, 2025, 3:59 PM
65.84
-0.24%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 66
Market Cap 1.23B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -9.17
PE Ratio (ttm) -7.2
Forward PE n/a
Analyst Buy
Ask 72
Volume 252,025
Avg. Volume (20D) 334,175
Open 65.30
Previous Close 64.02
Day's Range 64.26 - 67.87
52-Week Range 33.01 - 86.93
Beta undefined

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 82
Stock Exchange NASDAQ
Ticker Symbol PRAX

Analyst Forecast

According to 9 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $150, which is an increase of 127.27% from the latest price.

Buy 88.89%
Hold 11.11%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Praxis Precision Medicines Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of $365.00K, reflecting a -29.13% YoY shrinking and earnings per share of -2.82, making a -5.05% decrease YoY.
9 months ago · Source
+23.13%
Praxis Precision Medicines shares are trading high... Unlock content with Pro Subscription